It's good to see the advantages of this deal spelled out by the management. Adds some credibility to the discussions on this forum.
from the announcement....
'Compared to a traditional healthcare licensing agreement, the combination of the above
partnerships will optimise the requisite skill sets and provide a number of commercially
important advantages to Tissue Therapies including:
• Tissue Therapies will retain control of launch plans, messaging, promotions,
literature, advertising, sampling and individual country launches.
• Tissue Therapies will retain a higher % of net income.
• The sales staff will be focused exclusively on Tissue Therapies and selling
VitroGro® ECM. They will not be selling a large portfolio of products of which
VitroGro® ECM will be only one.
• The potential threats to VitroGro® ECM sales of a large partner’s competing internal
corporate strategies and changing priorities are avoided.
• Tissue Therapies retains complete flexibility to enter into other commercial
arrangements for global sales of VitroGro® ECM in the EU and globally.
- Forums
- ASX - By Stock
- TIS
- Ann: Investor Update
Ann: Investor Update , page-7
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TIS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
EL8
ELEVATE URANIUM LTD
Murray Hill, MD & CEO
Murray Hill
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online